Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic

Background and Aims: Recent reports have indicated that hepatic dysfunction occurred in a proportion of patients with coronavirus disease 2019 (COVID-19). We aimed to compare and describe the liver biomarkers in different subtypes of COVID-19 patients.Methods: This study enrolled 288 COVID-19 patien...

Full description

Bibliographic Details
Main Authors: Haozhi Fan, Jinyuan Cai, Anran Tian, Yuwen Li, Hui Yuan, Zhengyi Jiang, Yunxi Yu, Lili Ruan, Pingping Hu, Ming Yue, Nian Chen, Jun Li, Chuanlong Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.584888/full
id doaj-e657ac322c734c749507316ad56687a3
record_format Article
spelling doaj-e657ac322c734c749507316ad56687a32021-01-15T05:19:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-01-01710.3389/fmed.2020.584888584888Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of PandemicHaozhi Fan0Jinyuan Cai1Anran Tian2Yuwen Li3Hui Yuan4Zhengyi Jiang5Yunxi Yu6Lili Ruan7Pingping Hu8Ming Yue9Nian Chen10Jun Li11Chuanlong Zhu12Chuanlong Zhu13Department of Information, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, ChinaEmergency Department, Huangshi Hospital of Traditional Chinese Medicine, Huangshi, ChinaDepartment of Anesthesiology, The Fifth Hospital of Huangshi, Huangshi, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Tropical Diseases, The Second Affiliated Hospital of Hainan Medical University, Haikou, ChinaBackground and Aims: Recent reports have indicated that hepatic dysfunction occurred in a proportion of patients with coronavirus disease 2019 (COVID-19). We aimed to compare and describe the liver biomarkers in different subtypes of COVID-19 patients.Methods: This study enrolled 288 COVID-19 patients in Huangshi Hospital of Traditional Chinese Medicine. All patients were divided into ordinary, severe, and critical groups according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Demographic, clinical characteristics and liver biomarkers were compared among the three groups.Results: During hospitalization, AST, TBiL, and ALP levels in ordinary and severe patients fluctuated within the normal range with a rising trend in critical patients except AST. ALT and GGT levels fluctuated within the normal range showing an upward trend, while LDH levels in the critical group exceeded the normal range. Prealbumin showed an upward trend, especially in the severe group. At discharge, AST and LDH levels in ordinary and severe groups were lower than their baselines but increased in the critical group. In contrast to albumin, TBiL levels were increased in ordinary and critical groups while decreased in the severe group. The stratified analysis revealed factors affecting liver function in critical cases included highest temperature ≥38.0°C, age ≥60 and symptom of hypoxemia.Conclusions: COVID-19 can cause severe hepatic dysfunction in critical patients, requiring early monitoring and intervention. LDH, ALP, GGT, TBiL, prealbumin, and albumin may be helpful for evaluating and predicting disease prognosis due to their correlation with disease severity in COVID-19.https://www.frontiersin.org/articles/10.3389/fmed.2020.584888/fullCOVID-19SARS-CoV-2liver biomarkersliver injuryhepatic dysfunction
collection DOAJ
language English
format Article
sources DOAJ
author Haozhi Fan
Jinyuan Cai
Anran Tian
Yuwen Li
Hui Yuan
Zhengyi Jiang
Yunxi Yu
Lili Ruan
Pingping Hu
Ming Yue
Nian Chen
Jun Li
Chuanlong Zhu
Chuanlong Zhu
spellingShingle Haozhi Fan
Jinyuan Cai
Anran Tian
Yuwen Li
Hui Yuan
Zhengyi Jiang
Yunxi Yu
Lili Ruan
Pingping Hu
Ming Yue
Nian Chen
Jun Li
Chuanlong Zhu
Chuanlong Zhu
Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic
Frontiers in Medicine
COVID-19
SARS-CoV-2
liver biomarkers
liver injury
hepatic dysfunction
author_facet Haozhi Fan
Jinyuan Cai
Anran Tian
Yuwen Li
Hui Yuan
Zhengyi Jiang
Yunxi Yu
Lili Ruan
Pingping Hu
Ming Yue
Nian Chen
Jun Li
Chuanlong Zhu
Chuanlong Zhu
author_sort Haozhi Fan
title Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic
title_short Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic
title_full Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic
title_fullStr Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic
title_full_unstemmed Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic
title_sort comparison of liver biomarkers in 288 covid-19 patients: a mono-centric study in the early phase of pandemic
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-01-01
description Background and Aims: Recent reports have indicated that hepatic dysfunction occurred in a proportion of patients with coronavirus disease 2019 (COVID-19). We aimed to compare and describe the liver biomarkers in different subtypes of COVID-19 patients.Methods: This study enrolled 288 COVID-19 patients in Huangshi Hospital of Traditional Chinese Medicine. All patients were divided into ordinary, severe, and critical groups according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Demographic, clinical characteristics and liver biomarkers were compared among the three groups.Results: During hospitalization, AST, TBiL, and ALP levels in ordinary and severe patients fluctuated within the normal range with a rising trend in critical patients except AST. ALT and GGT levels fluctuated within the normal range showing an upward trend, while LDH levels in the critical group exceeded the normal range. Prealbumin showed an upward trend, especially in the severe group. At discharge, AST and LDH levels in ordinary and severe groups were lower than their baselines but increased in the critical group. In contrast to albumin, TBiL levels were increased in ordinary and critical groups while decreased in the severe group. The stratified analysis revealed factors affecting liver function in critical cases included highest temperature ≥38.0°C, age ≥60 and symptom of hypoxemia.Conclusions: COVID-19 can cause severe hepatic dysfunction in critical patients, requiring early monitoring and intervention. LDH, ALP, GGT, TBiL, prealbumin, and albumin may be helpful for evaluating and predicting disease prognosis due to their correlation with disease severity in COVID-19.
topic COVID-19
SARS-CoV-2
liver biomarkers
liver injury
hepatic dysfunction
url https://www.frontiersin.org/articles/10.3389/fmed.2020.584888/full
work_keys_str_mv AT haozhifan comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT jinyuancai comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT anrantian comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT yuwenli comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT huiyuan comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT zhengyijiang comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT yunxiyu comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT liliruan comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT pingpinghu comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT mingyue comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT nianchen comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT junli comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT chuanlongzhu comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
AT chuanlongzhu comparisonofliverbiomarkersin288covid19patientsamonocentricstudyintheearlyphaseofpandemic
_version_ 1724337670652428288